. Author manuscript; available in PMC: 2010 Jan 1.

Published in final edited form as: Ann Pharmacother. 2008 Nov 25;43(1):28–35. doi: 10.1345/aph.1L210

Table 2.

Outcomes of Patients Newly Colonized with Pseudomonas aeruginosa

Patient Outcome	MDR Pseudomonas (n = 20)	Non-MDR Pseudomonas (n = 55)	p Value
VAP due to P. aeruainosa, n (%)^a	9(45)	22 (40)	0.70
Non-Pseudomonas VAP, n (%)^a	2(10)	0(0)	0.07
Bacteremia with P. aeruginosa	2(10)	2(4)	0.29
Days from first positive culture to development of VAP, median	1 (1–5)	2.5(1–5)	0.92
Sepsis within 28 days after enrollment, n (%)	4(20)	11 (20)	1.0
Mortality, n (%)	(35)	16(29)	0.62

MDR = multidrug-resistant; VAP = ventilator-associated pneumonia.

Within 28 days after enrollment or until discharged from the intensive care unit.